Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views

In the latest quarter, 4 analysts provided ratings for Kymera Therapeutics KYMR, showcasing a mix of bullish and bearish perspectives.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $39.5, a high estimate of $55.00, and a low estimate of $26.00. Surpassing the previous average price target of $38.00, the current average has increased by 3.95%.

Exploring Analyst Ratings: An In-Depth Overview

The standing of Kymera Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Kymera Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Kymera Therapeutics compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Kymera Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Kymera Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Kymera Therapeutics analyst ratings.

About Kymera Therapeutics

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Kymera Therapeutics: Delving into Financials

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Revenue Challenges: Kymera Therapeutics's revenue growth over 3 months faced difficulties. As of 30 September, 2023, the company experienced a decline of approximately -50.5%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Kymera Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1118.17% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Kymera Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -12.72%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Kymera Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -9.32%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Kymera Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 0.2. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

The Core of Analyst Ratings: What Every Investor Should Know

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.